Dyne Therapeutics Q4 EPS $(1.09) Misses $(0.92) Estimate, Cash Balance of $123.1M
Portfolio Pulse from Benzinga Newsdesk
Dyne Therapeutics (NASDAQ:DYN) reported a Q4 EPS loss of $(1.09), missing the consensus estimate of $(0.92) by 18.48%. This represents a 47.3% increase in losses compared to the same period last year. The company also reported a cash balance of $123.1M.
March 05, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Dyne Therapeutics reported a larger than expected Q4 EPS loss and an increase in losses year-over-year, with a current cash balance of $123.1M.
The reported earnings miss and increased losses year-over-year are likely to negatively impact investor sentiment in the short term, leading to a potential decrease in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100